Our mission
To transform the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.
Our vision
Patients with rare neuroendocrine diseases are able to live their fullest lives and are transformed through optimal, stigma-free care.
It takes great people to make a great company
It’s the people that make Rhythm so special.
Our path to transforming the care of rare melanocortin-4 receptor (MC4R) pathway diseases
2008
Founded in Boston
2016
Phase 2 results in POMC deficiency published in the New England Journal of Medicine
2018
Phase 2 results in LEPR deficiency published in Nature Medicine
2020
FDA approves IMCIVREE for obesity due to POMC and LEPR deficiency
2022
IMCIVREE approved for BBS in US and Europe
2024
First-ever patients dosed with RM-718
Acquired oral MC4R agonist LB54640 from LG Chem Life Sciences
2011
First patients dosed with setmelanotide
2017
Initial Public Offering completed on Nasdaq
2019
Phase 3 trial in POMC deficiency initiated
2021
European Commission authorizes IMCIVREE for obesity due to POMC and LEPR deficiency
2023
Acquires Xinvento
Initiates Phase 3 trial in acquired hypothalamic obesity
2008
Founded in Boston
2011
First patients dosed with setmelanotide
2016
Phase 2 results in POMC deficiency published in the New England Journal of Medicine
2017
Initial Public Offering completed on Nasdaq
2018
Phase 2 results in LEPR deficiency published in Nature Medicine
2019
Phase 3 trial in POMC deficiency initiated
2020
FDA approves IMCIVREE for obesity due to POMC and LEPR deficiency
2021
European Commission authorizes IMCIVREE for obesity due to POMC and LEPR deficiency
2022
IMCIVREE approved for BBS in US and Europe
2023
Acquires Xinvento
Initiates Phase 3 trial in hypothalamic obesity
2024
First-ever patients dosed with RM-718
Acquired oral MC4R agonist LB54640 from LG Chem Life Sciences
Our story
Rhythm was founded in 2008 in Boston.
Our lead asset, IMCIVREE® (setmelanotide), FDA-approved in 2020, is a precision medicine designed to treat severe obesity caused by an impairment of a pathway in the hypothalamus called the MC4R pathway.
Rhythm became a publicly traded company in 2017. Now, we have grown to more than 250 employees in North America and Europe. With a robust clinical trials program, we remain poised for even more growth in the near future. As we continue to grow, the one thing that will never change is our commitment to patients.
Our leadership team is passionate about developing new therapies for patients.
Our employees strive every day to pioneer a path forward for patients and families living with rare neuroendocrine diseases.